Natco Pharma gets EIR from USFDA on pharmacovigilance requirements
The receipt of the EIR confirms the closure of the inspection process, prompting a positive market response with Natco Pharma's stock gaining 1.49 per cent on the BSE23-04-2024
23-04-2024
NATCO PHARMA LTD. - 524816 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (LODR) Regulations, 201523-04-2024
Natco Pharma Receives Warning Letter From USFDA Over Manufacturing Lapses At Telangana Plant
In the warning letter to the Natco Pharma, U.S. Food and Drug Administration said its investigators observed various violations at the finished pharmaceuticals plant located at Kothur Village in Telangana.21-04-2024
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate20-04-2024
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meet on 22nd April, 202418-04-2024
Natco Pharma Receives Warning Letter From US Health Regulator
The inspection by the USFDA was conducted from Oct. 9 to Oct. 18, 2023.09-04-2024
NATCO PHARMA LTD. - 524816 - Update On USFDA Inspection At Natco'S Manufacturing Facility In Kothur, Telangana
Update on USFDA inspection at NATCO''s Manufacturing facility in Kothur, Telangana09-04-2024
NATCO PHARMA LTD. - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulation, 201806-04-2024
NATCO PHARMA LTD. - 524816 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyNATCO PHARMA LTD. 2CIN NO.L24230TG1981PLC003201 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: CH VENKAT RAMESH Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: VENKATRAMESH.CH@NATCOPHARMA.CO.IN Name of the Chief Financial Officer: S V V N APPA RAO Designation: CHIEF FINANCIAL OFFICER EmailId: SVVN@NATCOPHARMA.CO.IN Date: 05/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.05-04-2024